Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PROTHENA CORP PUBLIC LTD COPRTA · Entity 2375 | Director · President and CEO | July 28, 2026 | July 31, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PROTHENA CORP PUBLIC LTD CO
Report date July 28, 2026 · Filed July 31, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, par value $0.01 per shareSEC Table I · non-derivative | Direct | 68,793 |
Ending reported balance
After 2026-07-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-28 · Exercise / conversion · Acquired 84,000 · Balance 152,793 F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Ordinary Shares upon vesting. Row 2 · 2026-07-28 · Disposition to issuer · Disposed 84,000 · Balance 68,793 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-07-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-28 · Exercise / conversion · Disposed 84,000 · Balance 0 F2: These RSUs reported in Table II were granted to the Reporting Person on July 28, 2025 as part of an aggregate award of 140,000 RSUs and initially reported in Table I of the Form 4 filed on July 30, 2025, because they were solely settleable in shares at the time of grant. These RSUs are being moved to Table II as of this Form 4. F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Ordinary Shares upon vesting. F3: These RSUs reported in Table II are fully vested as of July 28, 2026 (the one-year anniversary of the grant date). The remainder of the 140,000 RSUs reported in Table I (56,000 RSUs) are subject to vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Ordinary Shares upon vesting.
F2: These RSUs reported in Table II were granted to the Reporting Person on July 28, 2025 as part of an aggregate award of 140,000 RSUs and initially reported in Table I of the Form 4 filed on July 30, 2025, because they were solely settleable in shares at the time of grant. These RSUs are being moved to Table II as of this Form 4.
F3: These RSUs reported in Table II are fully vested as of July 28, 2026 (the one-year anniversary of the grant date). The remainder of the 140,000 RSUs reported in Table I (56,000 RSUs) are subject to vesting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 28, 2026 Filed Jul 31, 2026 00:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionRestricted Stock Units · Derivative | 84,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-003412 · form4.xml · derivative · entry 3 Kinney Gene G. · CIK 0001564380 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 84,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: These RSUs reported in Table II were granted to the Reporting Person on July 28, 2025 as part of an aggregate award of 140,000 RSUs and initially reported in Table I of the Form 4 filed on July 30, 2025, because they were solely settleable in shares at the time of grant. These RSUs are being moved to Table II as of this Form 4. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Ordinary Shares upon vesting. F3 · derivative.exercise_date: These RSUs reported in Table II are fully vested as of July 28, 2026 (the one-year anniversary of the grant date). The remainder of the 140,000 RSUs reported in Table I (56,000 RSUs) are subject to vesting. F3 · derivative.expiration_date: These RSUs reported in Table II are fully vested as of July 28, 2026 (the one-year anniversary of the grant date). The remainder of the 140,000 RSUs reported in Table I (56,000 RSUs) are subject to vesting. Read SEC document |
| July 28, 2026 Filed Jul 31, 2026 00:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Disposition to issuerOrdinary Shares, par value $0.01 per share | 84,000 | $8.56 | $719,040.00 |
DisclosureSEC source: 0000905148-26-003412 · form4.xml · nonDerivative · entry 2 Kinney Gene G. · CIK 0001564380 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,793 Read SEC document |
| July 28, 2026 Filed Jul 31, 2026 00:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 84,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905148-26-003412 · form4.xml · nonDerivative · entry 1 Kinney Gene G. · CIK 0001564380 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,793 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Ordinary Shares upon vesting. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:49 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 520,000 | $0.00 Strike: $9.36 | $0.00 |
DisclosureSEC source: 0000905148-26-001176 · form4.xml · derivative · entry 1 Kinney Gene G. · CIK 0001564380 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 520,000 Underlying: Ordinary Shares · 520,000 shares Expires 2036-03-03 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on March 3, 2027, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| July 28, 2025 Filed Jul 30, 2025 21:50 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantOrdinary Shares, par value $0.01 per share | 140,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-002656 · form4.xml · nonDerivative · entry 1 Kinney Gene G. · CIK 0001564380 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,793 Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 375,000 | $0.00 Strike: $14.95 | $0.00 |
DisclosureSEC source: 0000905148-25-000884 · form4.xml · derivative · entry 1 Kinney Gene G. · CIK 0001564380 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 375,000 Underlying: Ordinary Shares · 375,000 shares Expires 2035-03-05 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on March 5, 2026, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| February 27, 2024 Filed Mar 1, 2024 02:03 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 307,000 | $0.00 Strike: $30.30 | $0.00 |
DisclosureSEC source: 0000905148-24-000836 · form4.xml · derivative · entry 1 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 307,000 Underlying: Ordinary Shares · 307,000 shares Expires 2034-02-27 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 27, 2025, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| May 17, 2023 Filed May 18, 2023 01:54 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $29.81 | $0.00 |
DisclosureSEC source: 0001140361-23-025344 · form4.xml · derivative · entry 5 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 45,000 shares Expires 2024-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: All shares subject to the option have fully vested. F6 · balance_after: The Reporting Person holds options that give him the right to acquire an aggregate of 2,114,700 shares at exercise prices ranging from $12.15 to $52.97, of which 1,626,365 are currently exercisable, and 488,335 are currently unexercisable but vest over time, subject to the Reporting Person's continued employment with the Issuer on each applicable vesting date of each option award. Read SEC document |
| May 17, 2023 Filed May 18, 2023 01:54 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 14,934 | $74.49 | $1,112,500.86 |
DisclosureSEC source: 0001140361-23-025344 · form4.xml · nonDerivative · entry 4 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,793 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 6, 2023. F4 · price: The transaction was executed in multiple trades in prices ranging from $74.06 to $74.99, inclusive. Read SEC document |
| May 17, 2023 Filed May 18, 2023 01:54 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 19,864 | $73.60 | $1,462,069.86 |
DisclosureSEC source: 0001140361-23-025344 · form4.xml · nonDerivative · entry 3 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,727 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 6, 2023. F3 · price: The transaction was executed in multiple trades in prices ranging from $73.06 to $74.05, inclusive. Read SEC document |
| May 17, 2023 Filed May 18, 2023 01:54 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 10,202 | $72.70 | $741,721.11 |
DisclosureSEC source: 0001140361-23-025344 · form4.xml · nonDerivative · entry 2 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,591 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 6, 2023. F2 · price: The transaction was executed in multiple trades in prices ranging from $72.06 to $73.055, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the ranges set forth in footnotes 2 through 4 of this Form 4. Read SEC document |
| May 17, 2023 Filed May 18, 2023 01:54 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 45,000 | $29.81 | $1,341,450.00 |
DisclosureSEC source: 0001140361-23-025344 · form4.xml · nonDerivative · entry 1 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,793 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2023 Filed Mar 4, 2023 02:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 155,000 | $0.00 Strike: $52.97 | $0.00 |
DisclosureSEC source: 0001140361-23-010181 · form4.xml · derivative · entry 1 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,000 Underlying: Ordinary Shares · 155,000 shares Expires 2033-03-02 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on March 2, 2024 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. F2 · balance_after: The Reporting Person holds options that give him the right to acquire an aggregate of 2,159,700 shares at exercise prices ranging from $12.15 to $52.97, of which 1,642,200 are currently exercisable, and 517,500 are currently unexercisable but vest over time, subject to the Reporting Person's continued employment with the Issuer on each applicable vesting date of each option award. Read SEC document |
| September 28, 2022 Filed Oct 1, 2022 01:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,412 | $0.00 Strike: $6.41 | $0.00 |
DisclosureSEC source: 0001140361-22-035564 · form4.xml · derivative · entry 12 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 16,412 shares Expires 2023-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option was granted on January 29, 2013 and all shares subject to the option were fully vested and exercisable. The option will expire in approximately four months and be forfeited to the extent it is not exercised on or prior to January 29, 2023. F10 · balance_after: The Reporting Person holds options that give him the right to acquire an aggregate of 2,004,700 shares at exercise prices ranging from $12.15 to $32.45, of which 1,507,303 are currently exercisable, and 497,397 are currently unexercisable but vest over time, subject to the Reporting Person's continued employment with the Issuer on each applicable vesting date of each option award. Read SEC document |
| September 28, 2022 Filed Oct 1, 2022 01:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 129 | $58.93 | $7,601.97 |
DisclosureSEC source: 0001140361-22-035564 · form4.xml · nonDerivative · entry 11 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,793 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| September 28, 2022 Filed Oct 1, 2022 01:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 243 | $57.70 | $14,021.85 |
DisclosureSEC source: 0001140361-22-035564 · form4.xml · nonDerivative · entry 10 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,922 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F8 · price: The transaction was executed in multiple trades in prices ranging from $57.37 to $58.08, inclusive. Read SEC document |
| September 28, 2022 Filed Oct 1, 2022 01:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 40 | $56.19 | $2,247.66 |
DisclosureSEC source: 0001140361-22-035564 · form4.xml · nonDerivative · entry 9 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,165 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F7 · price: The transaction was executed in multiple trades in prices ranging from $56.115 to $56.34, inclusive. Read SEC document |
| September 28, 2022 Filed Oct 1, 2022 01:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 1,342 | $55.32 | $74,244.27 |
DisclosureSEC source: 0001140361-22-035564 · form4.xml · nonDerivative · entry 8 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,205 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · price: The transaction was executed in multiple trades in prices ranging from $54.995 to $55.94, inclusive. Read SEC document |
| September 28, 2022 Filed Oct 1, 2022 01:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 4,748 | $54.38 | $258,177.25 |
DisclosureSEC source: 0001140361-22-035564 · form4.xml · nonDerivative · entry 7 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,547 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · price: The transaction was executed in multiple trades in prices ranging from $53.96 to $54.91, inclusive. Read SEC document |
| September 28, 2022 Filed Oct 1, 2022 01:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 5,852 | $53.40 | $312,476.90 |
DisclosureSEC source: 0001140361-22-035564 · form4.xml · nonDerivative · entry 6 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,295 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The transaction was executed in multiple trades in prices ranging from $52.96 to $53.92, inclusive. Read SEC document |
| September 28, 2022 Filed Oct 1, 2022 01:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 2,333 | $52.44 | $122,341.82 |
DisclosureSEC source: 0001140361-22-035564 · form4.xml · nonDerivative · entry 5 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,147 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $51.95 to $52.93, inclusive. Read SEC document |
| September 28, 2022 Filed Oct 1, 2022 01:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 552 | $51.30 | $28,317.54 |
DisclosureSEC source: 0001140361-22-035564 · form4.xml · nonDerivative · entry 4 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,480 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $50.84 to $51.785, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in footnotes 2 through 8 of this Form 4. Read SEC document |
| September 28, 2022 Filed Oct 1, 2022 01:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 128 | $49.41 | $6,324.48 |
DisclosureSEC source: 0001140361-22-035564 · form4.xml · nonDerivative · entry 3 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,032 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| September 28, 2022 Filed Oct 1, 2022 01:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 1,045 | $48.09 | $50,254.05 |
DisclosureSEC source: 0001140361-22-035564 · form4.xml · nonDerivative · entry 2 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,160 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| September 28, 2022 Filed Oct 1, 2022 01:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 16,412 | $6.41 | $105,200.92 |
DisclosureSEC source: 0001140361-22-035564 · form4.xml · nonDerivative · entry 1 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,205 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 21, 2022 Filed Sep 24, 2022 01:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,720 | $0.00 Strike: $6.41 | $0.00 |
DisclosureSEC source: 0001140361-22-034588 · form4.xml · derivative · entry 3 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,412 Underlying: Ordinary Shares · 2,720 shares Expires 2023-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option was granted on January 29, 2013 and all shares subject to the option were fully vested and exercisable. The option will expire in approximately four months and be forfeited to the extent it is not exercised on or prior to January 29, 2023. F4 · balance_after: The Reporting Person holds options that give him the right to acquire an aggregate of 2,021,112 shares at exercise prices ranging from $6.41 to $32.45, of which 1,509,237 are currently exercisable, and 511,875 are currently unexercisable but vest over time, subject to the Reporting Person's continued employment with the Issuer on each applicable vesting date of each option award. Read SEC document |
| September 21, 2022 Filed Sep 24, 2022 01:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 2,720 | $32.02 | $87,089.78 |
DisclosureSEC source: 0001140361-22-034588 · form4.xml · nonDerivative · entry 2 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,793 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $32.00 to $32.11, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 21, 2022 Filed Sep 24, 2022 01:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 2,720 | $6.41 | $17,435.20 |
DisclosureSEC source: 0001140361-22-034588 · form4.xml · nonDerivative · entry 1 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,513 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 17, 2022 Filed Aug 20, 2022 01:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,181 | $0.00 Strike: $6.41 | $0.00 |
DisclosureSEC source: 0001567619-22-016512 · doc1.xml · derivative · entry 3 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,132 Underlying: Ordinary Shares · 2,181 shares Expires 2023-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option was granted on January 29, 2013 and all shares subject to the option were fully vested and exercisable. The option will expire in approximately six months and be forfeited to the extent it is not exercised on or prior to January 29, 2023. F4 · balance_after: The Reporting Person holds options that give him the right to acquire an aggregate of 2,023,832 shares at exercise prices ranging from $6.41 to $32.45, of which 1,497,476 are currently exercisable, and 526,356 are currently unexercisable but vest over time, subject to the Reporting Person's continued employment with the Issuer on each applicable vesting date of each option award. Read SEC document |
| August 17, 2022 Filed Aug 20, 2022 01:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 2,181 | $32.03 | $69,854.59 |
DisclosureSEC source: 0001567619-22-016512 · doc1.xml · nonDerivative · entry 2 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,793 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $32.00 to $32.09, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 17, 2022 Filed Aug 20, 2022 01:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 2,181 | $6.41 | $13,980.21 |
DisclosureSEC source: 0001567619-22-016512 · doc1.xml · nonDerivative · entry 1 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,974 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2022 Filed Aug 13, 2022 01:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,284 | $0.00 Strike: $6.41 | $0.00 |
DisclosureSEC source: 0001140361-22-029517 · form4.xml · derivative · entry 9 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,313 Underlying: Ordinary Shares · 20,284 shares Expires 2023-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option was granted on January 29, 2013 and all shares subject to the option were fully vested and exercisable. The option will expire in approximately six months and be forfeited to the extent it is not exercised on or prior to January 29, 2023. F6 · balance_after: The Reporting Person holds options that give him the right to acquire an aggregate of 2,026,013 shares at exercises prices ranging from $6.41 to $32.45, of which 1,499,657 are currently exercisable, and 526,356 are currently unexercisable but vest over time, subject to the Reporting Person's continued employment with the Issuer on each applicable vesting date of each option award. Read SEC document |
| August 12, 2022 Filed Aug 13, 2022 01:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 20,284 | $32.16 | $652,290.84 |
DisclosureSEC source: 0001140361-22-029517 · form4.xml · nonDerivative · entry 6 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,793 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The transaction was executed in multiple trades in prices ranging from $32.00 to $32.35, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 12, 2022 Filed Aug 13, 2022 01:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 20,284 | $6.41 | $130,020.44 |
DisclosureSEC source: 0001140361-22-029517 · form4.xml · nonDerivative · entry 5 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,077 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 11, 2022 Filed Aug 13, 2022 01:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,650 | $0.00 Strike: $6.41 | $0.00 |
DisclosureSEC source: 0001140361-22-029517 · form4.xml · derivative · entry 8 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,597 Underlying: Ordinary Shares · 13,650 shares Expires 2023-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option was granted on January 29, 2013 and all shares subject to the option were fully vested and exercisable. The option will expire in approximately six months and be forfeited to the extent it is not exercised on or prior to January 29, 2023. Read SEC document |
| August 11, 2022 Filed Aug 13, 2022 01:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 13,650 | $32.16 | $438,930.77 |
DisclosureSEC source: 0001140361-22-029517 · form4.xml · nonDerivative · entry 4 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,793 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $32.00 to $32.325, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 11, 2022 Filed Aug 13, 2022 01:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 13,650 | $6.41 | $87,496.50 |
DisclosureSEC source: 0001140361-22-029517 · form4.xml · nonDerivative · entry 3 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,443 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 10, 2022 Filed Aug 13, 2022 01:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 991 | $0.00 Strike: $6.41 | $0.00 |
DisclosureSEC source: 0001140361-22-029517 · form4.xml · derivative · entry 7 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,247 Underlying: Ordinary Shares · 991 shares Expires 2023-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option was granted on January 29, 2013 and all shares subject to the option were fully vested and exercisable. The option will expire in approximately six months and be forfeited to the extent it is not exercised on or prior to January 29, 2023. Read SEC document |
| August 10, 2022 Filed Aug 13, 2022 01:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 991 | $32.01 | $31,723.69 |
DisclosureSEC source: 0001140361-22-029517 · form4.xml · nonDerivative · entry 2 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,793 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $32.00 to $32.06, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 10, 2022 Filed Aug 13, 2022 01:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 991 | $6.41 | $6,352.31 |
DisclosureSEC source: 0001140361-22-029517 · form4.xml · nonDerivative · entry 1 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,784 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2022 Filed Aug 6, 2022 01:34 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 21,506 | $0.00 Strike: $6.41 | $0.00 |
DisclosureSEC source: 0001567619-22-015086 · doc1.xml · derivative · entry 7 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,238 Underlying: Ordinary Shares · 21,506 shares Expires 2023-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option was granted on January 29, 2013 and all shares subject to the option were fully vested and exercisable. The option will expire in approximately six months and be forfeited to the extent it is not exercised on or prior to January 29, 2023. F6 · balance_after: The Reporting Person holds options that give him the right to acquire an aggregate of 2,060,938 shares at exercises prices ranging from $6.41 to $32.45, of which 1,529,478 are currently exercisable, and 531,460 are currently unexercisable but vest over time, subject to the Reporting Person's continued employment with the Issuer on each applicable vesting date of each option award. Read SEC document |
| August 05, 2022 Filed Aug 6, 2022 01:34 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 4,673 | $33.06 | $154,504.80 |
DisclosureSEC source: 0001567619-22-015086 · doc1.xml · nonDerivative · entry 5 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,793 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · price: The transaction was executed in multiple trades in prices ranging from $33.00 to $33.14, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 05, 2022 Filed Aug 6, 2022 01:34 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 16,833 | $32.77 | $551,558.49 |
DisclosureSEC source: 0001567619-22-015086 · doc1.xml · nonDerivative · entry 4 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,466 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The transaction was executed in multiple trades in prices ranging from $32.00 to $32.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 05, 2022 Filed Aug 6, 2022 01:34 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 21,506 | $6.41 | $137,853.46 |
DisclosureSEC source: 0001567619-22-015086 · doc1.xml · nonDerivative · entry 3 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,299 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 04, 2022 Filed Aug 6, 2022 01:34 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,954 | $0.00 Strike: $6.41 | $0.00 |
DisclosureSEC source: 0001567619-22-015086 · doc1.xml · derivative · entry 6 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,744 Underlying: Ordinary Shares · 20,954 shares Expires 2023-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option was granted on January 29, 2013 and all shares subject to the option were fully vested and exercisable. The option will expire in approximately six months and be forfeited to the extent it is not exercised on or prior to January 29, 2023. Read SEC document |
| August 04, 2022 Filed Aug 6, 2022 01:34 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 20,954 | $32.18 | $674,316.48 |
DisclosureSEC source: 0001567619-22-015086 · doc1.xml · nonDerivative · entry 2 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,793 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $32.00 to $32.465, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 04, 2022 Filed Aug 6, 2022 01:34 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 20,954 | $6.41 | $134,315.14 |
DisclosureSEC source: 0001567619-22-015086 · doc1.xml · nonDerivative · entry 1 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,747 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 27, 2022 Filed Jul 30, 2022 01:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 376 | $0.00 Strike: $6.41 | $0.00 |
DisclosureSEC source: 0001140361-22-027528 · form4.xml · derivative · entry 3 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,698 Underlying: Ordinary Shares · 376 shares Expires 2023-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option was granted on January 29, 2013 and all shares subject to the option were fully vested and exercisable. The option will expire in approximately six months and be forfeited to the extent it is not exercised on or prior to January 29, 2023. F3 · balance_after: The Reporting Person holds options that give him the right to acquire an aggregate of 2,103,398 shares at exercises prices ranging from $6.41 to $32.45, of which 1,571,938 are currently exercisable, and 531,460 are currently unexercisable but vest over time, subject to the Reporting Person's continued employment with the Issuer on each applicable vesting date of each option award. Read SEC document |
| July 27, 2022 Filed Jul 30, 2022 01:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 376 | $32.00 | $12,032.00 |
DisclosureSEC source: 0001140361-22-027528 · form4.xml · nonDerivative · entry 2 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,793 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| July 27, 2022 Filed Jul 30, 2022 01:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 376 | $6.41 | $2,410.16 |
DisclosureSEC source: 0001140361-22-027528 · form4.xml · nonDerivative · entry 1 Kinney Gene G. · CIK 0001564380 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,169 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.